Moreover, recent studies have shown that ethnic disparity exists in clinical performance between MIA and ROMA (CA125 and HE4) in detection of ovarian malignancy risk. This is partially due to the fact that certain non-white populations, such as the African American population, are known to have lower circulating levels of CA125 . This, in turn, makes the assessment less effective in this population.
The MIA, Ova1, was shown to be superior to ROMA in the detection of ovarian cancer in African American women . It has been shown that the implementation of MIA in the evaluation of adnexal masses will increase the sensitivity of the detection of malignancy compared with ROMA and CA125 alone, with the most marked results in African American women [10,11]. Likewise, the MIA, Overa® (Aspira Women’s Health), was shown to outperform CA125 in Filipino women .
What future developments do you envisage or would like to see for ovarian cancer diagnosis?
Real success in the field of detection of ovarian cancer will rely on screening tests, coupled with ultrasound and clinical assessment. Those screening tests will help to identify patients with early stage ovarian cancer, when survival outcome is best achieved.
This goal of early detection is limited by the difficulty of defining ovarian cancer in its preclinical phase. There must also be continual efforts made to ensure that innovations in early cancer detection serve all patient populations equitably and effectively. Hope emanates from the development of new serum protein and genetic biomarkers for improved risk assessment and for the application of early detection biomarkers in these high-risk groups. If such markers are identified and become part of the standard of care, diagnostic intervention could initiate early treatment or preventive methods leading to improved survival and cure rate for this lethal disease.